Product Pipeline

Our innovative approach to drug development has resulted in a pipeline of drug candidates that offer novel, differentiated treatments for a range of chronic diseases, including autoimmune and central nervous system (CNS) diseases.

Lead Indications
Preclinical
Phase 1
Phase 2
Phase 3
plus-minus
CTP-543 Deuterated ruxolitinib
Alopecia Areata
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 

An investigational JAK inhibitor designed to target the immunological basis of alopecia areata. CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. Learn more >

plus-minus
CTP-692 Deuterated D-serine
Schizophrenia
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 
Additional CNS Indications
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 

An investigational deuterium-modified form of d-serine for the adjunctive treatment of schizophrenia. CTP-692 is being investigated as a treatment for positive and negative symptoms as well as cognitive dysfunction to more broadly treat the symptoms of schizophrenia than has been previously possible. Learn more >

plus-minus
AVP-786 Deudextromethorphan
Alzheimer's Agitation
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 
Neurologic/ Psychiatric Indications
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 

A combination of deudextromethorphan and an ultra-low dose of quinidine being investigated for the treatment of neurologic and psychiatric disorders including agitation associated with dementia of the Alzheimer’s type, under development by Avanir (a subsidiary of Otsuka). Learn more >

Strategic Collaborations

Concert’s platform has driven product development programs and resulted in novel drugs that are being developed under strategic collaborations.

Back to Top